FT : China’s slowdown is secular, not cyclical

It is very striking that western commentators and investors have become extremely sceptical about any good news emanating from the Chinese economy. This week, for example, official economic data showed growth in gross domestic product at a quarterly annualised rate of about 8 per cent, with industrial production bouncing back in September from a weak reading in August. Yet markets were unimpressed.

Although this latest news clearly reduced the danger that China is entering a hard landing as the property sector adjusts sharply, many headlines proclaimed, correctly, that the economy is now growing at the slowest pace since the last recession. So is China bouncing back from a weak patch of growth, or is it headed for a prolonged slowdown lasting many years?

Actually, both are probably true. Cyclical fluctuations are occurring around a clearly slowing long-term trend for growth, and this can defy simple good news/bad news interpretations. At present, it seems that the latest cyclical slowdown is being controlled, despite the property crash.

First, let us examine the latest fluctuations in the short-term cycle. According to the official data, real GDP growth has bounced back from its weakness at the start of the year, with two successive quarterly annualised growth rates at just above 8 per cent. Because the first-quarter of 2014 was extremely weak, however, the 12-month growth rate has slowed to about 7.3 per cent, which is fractionally lower than in the past couple of years.

The pessimists have focused on this, and on the fact that industrial production has slowed down more than real GDP. As usual, there is also widespread scepticism about the accuracy of official Chinese data, given that some series such as cement, steel and electricity production have plummeted.

The benign explanation for all this is that the industrial sectors closest to the property market are indeed suffering a hard landing, but this is being offset by firm growth in real retail sales, especially in the internet retail sector, which is up 50 per cent on last year. Growth in “new China” is offsetting the slowdown in “old China” in this interpretation. Another supportive factor has been firmness in exports, which is encouraging and somewhat surprising in view of growing pessimism about global economic activity.

The next few months will be crucial. The shake-out in the property sector will continue and, according to Goldman Sachs, this might reduce the contribution of housing investment to GDP growth from 1.8 per cent in 2013 to about 0.3 per cent by next year. This hit to growth has been met by a major easing in monetary conditions, which started in February and is still under way. Fiscal policy is also being fine tuned to ensure that the imploding housing sector does not cause a hard landing for the economy as a whole.

So far, so good, then on the latest cycle. But what about the longer term?

Until 2011, mainstream economic forecasters (such as the International Monetary Fund, for example) believed that the trend growth rate in China would remain in the 9-10 per cent region for as far ahead as the eye could see. Now almost no one thinks that. The IMF now seems to think that the trend growth rate is declining gradually to only about 6.3 per cent by about 2019. Others are more pessimistic. The Conference Board forecast this week that trend growth after 2020 would be only 4 per cent a year, and warned that this “long, soft fall” in growth would inevitably have painful patches.

The reasons given by forecasters for these large markdowns in China’s medium-term growth projections are familiar:

the need to reduce the rate of growth in credit/GDP ratio will slow the growth in investment;
as investment slows, the growth in industrial capacity, which has been the main source of expansion from the supply side, will drop;
the process of urbanisation will slow or even stop altogether, and the transport and housing infrastructure that is needed is already in place;
the reform of the financial sector will lead to higher interest rates and to much slower lending from shadow banks to the local government and other state-owned entities that have until recently been a prime source of growth.
This powerful set of factors underpins the much more cautious projections that have now become the norm for China’s medium-term growth rate. History has plenty of earlier examples of countries that have failed to live up to excessively optimistic extrapolations of spurts in GDP growth, including the Soviet Union in the 1980s, Japan in the 1990s and even Argentina a century ago.

Lawrence Summers and Lant Pritchett have just released an updated version of their fascinating study on the powerful nature of mean reversions in medium-term growth rates. These are replete in the historical database of economic growth rates. (See this excellent summary by David Keohane at FT Alphaville.)

Their key point is that high growth rates in the recent past do not offer much reason to believe that growth will be higher than the world average in the medium-term future. What goes up must come down, is the gist of the message. This applies in particular to growth spurts in emerging markets, and to situations in which there is a shift away from authoritarianism.

For China, they argue that “par” for the statistical course would involve a decline in the trend growth rate to only 5 per cent over the next 10 years, and to 3.9 per cent on average over the next two decades. The latest IMF and consensus forecasts for China’s medium-term growth rate have started to come more into line with the Summers/Pritchett norms, but they are not there yet.

In assessing Chinese growth data, investors therefore need to juggle with two different forces. First, the long-term trend growth rate is probably slowing from about 7.5 per cent now to, at best, 6 per cent by 2020 (with a lot of uncertainty around that). Second, there will be cyclical fluctuations around that trend, which the authorities will seek to smooth through policy changes.

Financial markets are likely to be sensitive not to the decline in the long-term trend, but to significant cyclical fluctuations below that trend (“hard landings”). The latest data are not indicative of a hard landing at present.

FT : Mylan tweaks $5bn ‘inversion’ deal

A US pharmaceuticals group vowed to push ahead with a $5bn deal designed to slash its tax bill but tweaked the transaction following a White House crackdown that has torpedoed a string of so-called “inversions”.
Mylan, the US generic drugs maker, said it would change the terms of its agreement to buy a unit of Abbott Laboratories for $5.3bn, a deal that would allow it to reincorporate as a Dutch company and cut its effective tax rate from 25 per cent to the “high teens”.

It comes just a month after the US Treasury launched a crackdown on inversions, leading to the collapse of AbbVie’s $53bn acquisition of Irish drugmaker Shire and Salix’s $2.7bn inversion deal with Italy’s Cosmo Pharmaceuticals.
In a regulatory filing on Wednesday, Mylan said it would give Abbott a slightly larger stake in the company – 22 per cent instead of 21 per cent – a move apparently designed to satisfy a US Treasury rule that requires inversions to have more than 20 per cent foreign ownership.
In return, Mylan would be able to buy products and services from Abbott at better prices. Investors in both companies reacted negatively to the revised terms, with shares in Mylan falling 3.14 per cent and Abbott falling 1.9 per cent.
Abbott is planning to spin off its generics business in developed markets outside of the US and to sell it to Mylan, which will then form an entirely new company incorporated in the Netherlands. The deal is known as a “spinversion” because Mylan is buying a discrete business division rather than an entire company.
The recent US crackdown had intended to strip so-called “spinversions” of any tax benefits, and Mylan’s decision to press ahead with the Abbott deal suggests this section of the Treasury’s new rules is not proving as effective as hoped.
“Abbott still plans to close its deal with Mylan in the first quarter of 2015, despite pressure on inversions from the US Treasury, and some walking away by other companies from inversions,” said Edward Jones analyst Jeff Windau. “The changes from Treasury are making people re-look at deal terms, and deals are not as favourable now. That’s what happened here: there had to be some tweaks.”
Mylan has been vocal about its need to pursue an inversion to stay competitive in the generic drugs business. In July, when the deal was announced, the company’s chief executive described Mylan as “the last Mohican standing”.
“We’re the last in our sector to have announced an inversion or to be domiciled outside the US,” she said at the time.

>>> JAPAN OCT PRELIM MARKIT/JMMA MANUFACTURING PMI: 52.8 V 51.7E (5th straight m

JAPAN OCT PRELIM MARKIT/JMMA MANUFACTURING PMI: 52.8 V 51.7E (5th straight month of expansion, highest since March) - Output 52.3 v 53.4 prior

- Output Increase, slower rate
- New Orders Increase, faster rate
- New Export Orders Increase, faster rate
- Employment Increase, change of direction
- Backlogs of Work Increase, change of direction
- Output Prices Increase, faster rate
- Input Prices Increase, faster rate
- Stocks of Purchases Increase, faster rate
- Stocks of Finished Goods Increase, faster rate
- Quantity of Purchases Increase, faster rate
- SuppliersDelivery Times Lengthened, faster rate

- No revision.

>>> CHINA HSBC OCT FLASH MANUFACTURING PMI: 50.4 V 50.2E (3-month high) - Output

CHINA HSBC OCT FLASH MANUFACTURING PMI: 50.4 V 50.2E (3-month high) - Output index 50.7 v 51.3 prior (5-month low)

- HSBC Chief Economist Qu Hongbin: "The HSBC China Manufacturing PMI improved to 50.4 in the flash reading for October, up from 50.2 in the final reading for September. Domestic as well as external demand showed some signs of slowing although both remained in expansion territory. Disinflationary pressures intensified, as both the input and output price indices declined further. Meanwhile both employment and inventory indices improved. While the manufacturing sector likely stabilized in October, the economy continues to show signs of insufficient effective demand. This warrants further policy easing and we expect more easing measures on both the monetary as well as fiscal fronts in the months ahead."

Components:
- Output Increase, slower rate
- New Orders Increase, slower rate
- New Export Orders Increase, slower rate
- Employment Decrease, slower rate
- Backlogs of Work Increase, slower rate
- Output Prices Decrease, faster rate
- Input Prices Decrease, faster rate
- Stocks of Purchases Decrease, faster rate
- Stocks of Finished Goods Increase, from decrease
- Quantity of Purchases Increase, slower rate
- Suppliers Delivery Times Lengthening, faster rate

>>> US After Hours SCSS +11.7%, TSCO +10.9%, ALB +2.3%, AIRM

After Hours Summary: SCSS +11.7%, TSCO +10.9%, ALB +2.3%, AIRM -19.8%, YELP -13.2%, WYY -8.1%, CLB -7.9% following earnings/guidance

After Hours Gainers:

Companies trading higher in after hours in reaction to earnings: SCSS +11.7%, TSCO +10.9%, INFN +9.7%, ACTG +7.7%, EGHT +7.5%, MKTO +4.5%, ORLY +4.2%, MLNX +2.7%, ALB +2.3%, DMRC +1.6%, SHLM +1.6%, FTNT +1.5%, ORRF +1.3%, LEG +0.6%, EFX +0.5%, TAL +0.4%, SLG +0.4%, BCR +0.3%, RE +0.3%, LHO +0.1%

Companies trading higher in after hours in reaction to news: CYTX +60.1% (received FDA approval to resume ATHENA trial enrollment), PH +4.5% (increased quarterly dividend 31% to $0.63, up from $0.48, and authorizes the repurchase of up to 35 mln shares), STX +1.9% (raised targeted annual dividend 26% to $2.16, up from previous annual dividend of $1.72), KMX +1.0% (increased share repurchase authorization by $2 bln), V +1.0% (increased quarterly dividend 20% to $0.48 from $0.40 per share), 

After Hours Losers:

Companies trading lower in after hours in reaction to earnings: AIRM -19.8%, YELP -13.2%, WYY -8.1%, CLB -7.9%, CAKE -5.8%, CTXS -5.7%, VAR -4.9%, AWH -4.7%, NMFC -4.4%, OTEX -3.9%, LRCX -3.3%, TER -2.2%, SUSQ -2.1%, T -1.5%, CA -1.3%, SKX -0.3%

Companies trading lower in after hours in reaction to news: FREE -20.5% (filed for 17.5 mln share common stock offering by selling stockholder), ADHD -17.1% (co released a presentation with updated clinical trial results of Metadoxine Extended Release for the treatment of ADHD), WYY -8.1% (announced proposed public offering of common stock), NMFC -4.4% (commenced offering of 5 mln shares of common shares 

>>> 3Q14 Conference Call Mellanox

3Q14 Conference Call Mellanox

23. October 2014


CC with Eyal Waldman, Chairman and CEO, and Yakov Shulman, CFO

Summary:

The main growth element that was seen in 3Q was related to the refreshment cycle in the HPC (High Performance Computing) market. The CPU refreshment cycle should continue for 4-6 quarters and is likely to show significant growth for the company. The new CPU enables a more powerful system and enhances Mellanox's unique position within the market.
The cloud segment has seen significant upside with the CloudX solutions that should be enhanced in the near future with applications in the e-Commerce and Big Data segments.
Mellanox reported that it has seen considerable traction as well in the storage market and this market is obviously seeing the advantages of using Mellanox's solutions. Web 2.0 providers should continue to grow in the future.
Mellanox continues to invest in the Ethernet market and invest in the cable business (acquisitions were made in the cable business in FY13)
IC and Boards made up 51% of revenues. InfiniBand made up 61% of revenues an increase from 50% of revenues. Ethernet revenues made up 16% of revenues.
In total, Mellanox reported that 37% of its quarterly revenues stemmed from more than 10% customers (HP 15%, IBM 11%, and Dell 11%).
The company sees increased transitioning from 10Gbps Ethernet solutions to 40Gbps Ethernet solutions that should be able to deal with the exponential growth of data. This trend should continue towards 2015 and beyond.
Mellanox expects 2015 to be growth year.
The company isn't able to fully relate the Grantley refreshment cycle to the Romley refreshment cycle. However, this cycle is likely to be more stretched out than the Romley cycle that was delayed, creating a heavy quarterly demand for a certain amount of products.
Mellanox didn't give any details when the 100Gbps solutions will start shipping.
The company affirmed that the HPC business continues to be the strongest growth engine for the stock.
OpEx continues to grow due to acquired IPtronics and Kotura acquisitions in 2013.

Comments:

This was a very strong quarter for the company. The bottom-line was a real surprise and the forward looking guidance seems to be stronger than expected. Thus, short sighted investor might see this as a buying opportunity.
Mellanox's 3Q gross margins are likely to have been reported higher due to the increased InfiniBand revenue share that increased 11 percentage points from last quarter.
The InfiniBand exposure should stay similar or even larger in the refreshment cycle and the strong growth segment should be the 40Gbps Ethernet solutions when looking at the overall market (MLNX's Ethernet share is only 16% in this quarter).
The problem with Ethernet is that the competition is much larger and the amount of profitability in this segment is much lower (except plain 40Gbps).
Further, the only real growth engine for Mellanox seems to be the HPC market that continues to maintain a 50% revenue share.
The Grantley growth, as we've stated in the past, is likely to continue to stay at a rather low level when compared to the Romley refreshment cycle (due to the prolonged cycle).
What happens after the refreshment cycle? We believe that this would be a continuation of the slow-mid growth cycle and at the same time the increased costs of the integration of the two new acquisitions (IPtronics and Kotura) should be rather less beneficial for the shareholder. This puts pressure on the FY16 and FY17 estimates.
We believe that this turns Mellanox from a high growth stock to a mid-low growth stock. Does this justify a P/E of 49.55 for FY14 according to Bloomberg consensus estimates? We believe that this isn't the case.
Investors should be seeking to exit the stock in our opinion. This is definitely not the growth story that we would expect.

>>> US Close Dow-0,92% s&p-0,73% nasdaq-0,83% russell-1,44%

Closing Market Summary: S&P 500 Snaps Four-Day Winning Streak

The stock market ended the midweek session on a lower note, causing the S&P 500 (-0.7%) to snap its four-day winning streak. The benchmark index slumped into the red during afternoon action while the Dow Jones Industrial Average (-0.9%) underperformed once again.

Equity indices displayed modest gains in the early going, but that advance took place despite the lack of concerted leadership. The underperformance of several influential sectors weighed on the market and led to a mid-session retreat.

Five of six cyclical sectors ended behind the broader market with energy (-1.7%) showing the largest decline. The growth-sensitive sector displayed intraday strength, but slumped in the afternoon amid weakness in crude oil. The energy component spent the morning near its flat line, but plunged in the afternoon to end lower by 2.4% at $80.49/bbl. Greenback strength acted as a bit of a headwind with the Dollar Index (85.75, +0.45) rising 0.5%.

Ending just ahead of energy was the industrial sector (-1.3%), which was pressured by Boeing (BA 121.45, -5.67). The Dow component reported better than expected results, but fell 4.5% amid concerns about increasing production costs for its Dreamliner jet.

Transport stocks also weighed on the sector with the Dow Jones Transportation Average falling 2.1%. The bellwether complex narrowed this week's gain to 2.0% after Ryder (R 81.17, -5.89) and Norfolk Southern (NSC 106.50, -3.35) reported earnings. Ryder missed top-line estimates while Norfolk Southern reported disappointing earnings and revenue.

Elsewhere, the technology sector (-0.6%) was the lone outperformer among cyclical groups. Broadcom (BRCM 39.37, +2.04) surged 5.5% in reaction to better than expected results while most large cap components ended in the red. Apple (AAPL 102.99, +0.52) and Google (GOOGL 542.69, +4.66) bucked the trend, climbing 0.5% and 0.9%, respectively. Chipmakers finished among the laggards with the PHLX Semiconductor Index falling 1.4%.

The underperformance of microchip names pressured the Nasdaq (-0.8%), which also faced weakness in the biotech space. Biogen Idec (BIIB 309.07, -17.70) sank 5.4% after investors overlooked better than expected earnings, instead focusing on slowing sales of the company's main drug. The iShares Nasdaq Biotechnology ETF (IBB 276.24, -2.03) lost 0.7% while the health care sector shed 0.6%.

On the upside, countercyclical consumer staples (+0.1%) and utilities (+0.6%) displayed relative strength throughout the session. The utilities sector extended its October gain to 4.6%.

Treasuries ended flat after reclaiming their intraday losses. The 10-yr yield finished at 2.22%.

Participation was above average with more than 779 million shares changing hands at the NYSE floor.

Economic data was limited to the MBA Mortgage Index and CPI:
  • The weekly MBA Mortgage Index spiked 11.6% to follow last week's increase of 5.6% 
  • CPI and core CPI both ticked up 0.1% (CPI consensus 0.0%; Core CPI consensus +0.2%) 
    • Energy prices declined 0.7%, representing the third monthly decrease 
    • Food prices, meanwhile, increased 0.3% after rising 0.2% in August with beef and veal prices rising 2.0% to bring their 2014 increase to 16.7% 
Tomorrow, weekly Initial Claims will be released at 8:30 ET (consensus 285K) while the FHFA Housing Price Index for August will cross the wires at 9:00 ET. The day's data will be topped off with the Leading Indicators report for September (consensus 0.5%), which will be released at 10:00 ET.
  • Nasdaq Composite +4.9% YTD 
  • S&P 500 +4.3% YTD 
  • Dow Jones Industrial Average -0.7% YTD 
  • Russell 2000 -5.7% YTD